Research-grade biosimilars for the analysis of biological processes Labmate Online
How do biosimilars contribute to drug discovery research?
Investigating the biological effects of a drug or developing proof-of-concept trials requires a drug source. In general, it is difficult to obtain original pharmaceutical grade biotherapeutic drugs for research rather than clinical application. Therefore, biologics that are nearly identical to a reference biologic drug (biosimilars) that have been approved by government regulatory authorities for medical treatment are essential research tools.
To develop an effective biologic drug, it is important to synthesize a reference antibody. A reference antibody can greatly facilitate the downstream development of a new biologic drug and can help identify critical cell lines, reagents and performance characteristics. AMSBIO The new line of biosimilar antibodies for research enables analysis of biological processes without the need to purchase expensive therapeutic grade biologics.
One of the main challenges in analyzing the impact of biosimilars is to obtain a validated positive control for in-situ analysis. For this task, FFPE cytosections of the HEK293T cell pellet that overexpress the targeted proteins are available from AMSBIO. These cells are obtained by transfection of a verified sequencing of transfected cDNA clones into HEK293T cells and the expression is verified by western blot and IHC analysis.
More information in line